Clinical trials: Cancer Patient
Prostate Cancer
Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2
Researchers in this study will determine whether providing decision support interventions (DESIs) to men with low risk prostate cancer improves their decision-specific knowledge and alters their treatment decisions.
- Trial name
- NCT01244568
- Testing
- Prostate cancer treatment DESI
- Where
- 2 sites in United States
- Volunteers
- 218 people
- Sponsor
- University of North Carolina, Chapel Hill
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
This phase I trial is studying the safety and potential efficacy of infusing non-human leukocyte antigen (HLA) matched ex vivo expanded cord blood progenitors following treatment with clofarabine and cytarabine for patients with…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01031368
- Testing
- cytarabine, clofarabine, filgrastim
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Nohla Therapeutics, Inc.
Prostate Cancer
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
The goal of this clinical trial is to evaluate whether adjuvant darolutamide plus androgen-deprivation therapy (ADT) can reduce post-operative recurrence and improve disease control in high-risk prostate cancer patients-defined…
- Trial name
- NCT07282197
- Testing
- Darolutamide (BAY 1841788)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University First Hospital
Breast Cancer
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with locally…
- Trial name
- NCT00045097
- Testing
- ixabepilone
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer, Breast, Cancer, Lung
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid…
- Conditions
- Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus
- Trial name
- NCT05830097
- Testing
- CBP-1019
- Where
- 5 sites in United States, China
- Volunteers
- 260 people
- Sponsor
- Coherent Biopharma (Hefei) Co., Ltd.
Depression, Psychological Distress
German Evaluation of the Effectiveness of the Psychological Intervention Managing Cancer and Living Meaningfully (CALM)
Purpose of this randomized controlled trial is to test the efficacy of the individual psychotherapeutic intervention Managing Cancer and Living Meaningfully (CALM) in a German sample of patients with advanced cancer.
- Trial name
- NCT02051660
- Testing
- Manualized CALM intervention, Non-manualized supportive intervention.
- Where
- 2 sites in Germany
- Volunteers
- 206 people
- Sponsor
- University of Leipzig
Lung Cancer, Venous Thromboembolism
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint…
- Conditions
- Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06950697
- Where
- 5 sites in China
- Volunteers
- 2,400 people
- Sponsor
- Beijing Chao Yang Hospital
Polycythemia Vera, Essential Thrombocythemia
Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients
Patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of…
- Trial name
- OUEST (NCT02893410)
- Where
- France
- Volunteers
- 286 people
- Sponsor
- University Hospital, Brest
Lung Cancer, Nonsmall Cell, Quality of Life
Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer
Lung cancer is the most common type of cancer and the leading cause of cancer death worldwide, in both men and women. Improvements in earlier preoperative staging and more effective adjuvant treatment have improved survival in…
- Conditions
- Lung Cancer, Nonsmall Cell, Quality of Life, Physical Disability, Surgery
- Trial name
- NCT05863013
- Testing
- ADL-Glittre Test
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Centro Universitário Augusto Motta
Melanoma Stage Iv, Metastatic Melanoma
Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet
This research will study the effect of Mediterranean diet intervention in patients undergoing immunotherapy treatment for metastatic melanoma and its relationship with gut microbiome and quality of life.
- Trial name
- MINI-MD (NCT06236360)
- Testing
- Mediterranean Diet Intervention
- Where
- Croatia
- Volunteers
- 30 people
- Sponsor
- University Hospital Rijeka
Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
The outcome of HMA-refractory patients with MDS or AML is dismal with a median survival of 5 months after failure, representing a significant unmet medical need due to the very limited treatment options.
- Trial name
- SAMBA (NCT02992860)
- Testing
- JNJ-56022473, Bone marrow analyses and CBC with differential, Flow cytometry analyses
- Where
- 10 sites in France, Germany
- Volunteers
- 25 people
- Sponsor
- GWT-TUD GmbH
Neoplasm Malignant
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma…
- Trial name
- NCT04401020
- Testing
- SAR442257
- Where
- 16 sites in United States, Czechia and 3 more
- Volunteers
- 47 people
- Sponsor
- Sanofi
Breast Cancer, Chronic Pain
Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms
Many breast cancer survivors report chronic pain that develops or worsens following chemotherapy. The impact of chemotherapy on the development of chronic pain is uncertain.
- Trial name
- NCT01983982
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan
Advanced Solid Tumors
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
A5301005 is a phase 1 study in patients with solid tumors which is testing the safety and tolerability of adding targeted agents to a standard chemotherapy.
- Trial name
- NCT00949624
- Testing
- CP-868,596, Docetaxel, AG-013736
- Where
- 2 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Overweight or Obese Breast Cancer Patients
Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer
The primary objective of MEDEA is to compare the effect of a personalised telephone-based health education weight loss program based on motivational coaching, exercise and diet versus a standard health educational program control…
- Trial name
- MEDEA (NCT04304924)
- Testing
- The personalized telephone based intervention
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Osteosarcoma, Sarcoma
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT05830123
- Testing
- HS-20093
- Where
- 11 sites in China
- Volunteers
- 170 people
- Sponsor
- Hansoh BioMedical R&D Company
Recurrent High Grade Glioma
PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas
This trial is an open-label, single-arm, phase 0/1 study of high-grade glioma that aims to evaluate the feasibility, preliminary efficacy and safety of the precision treatment strategy.
- Trial name
- NCT05473923
- Testing
- Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Head and Neck Cancer, Mucositis
Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis
Radiation treatment is very effective for treating cancers of the head and neck, however, during the course of treatment, it is common for patients to experience soreness of their mouth and throat due to the radiation.
- Trial name
- NCT00814359
- Testing
- Combination of Magic Mouthwash Plus Sucralfate, 0.15% Benzydamine HCl
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- Juravinski Cancer Centre Foundation
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
This is an exploratory study to assess [18F]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial.
- Trial name
- NCT04989959
- Testing
- [18F]PT2385, Positron Emission Tomography/Computed Tomography, Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Orhan Kemal Oz
Prostate Cancer
A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death
Primary objective of this study is to describe the time in each prostate cancer stage from non-metastatic Hormone Sensitive Prostate Cancer (m0HSPC), metastatic Hormone Sensitive Prostate Cancer (m1HSPC), non-metastatic…
- Trial name
- NCT03619980
- Testing
- No intervention
- Where
- Sweden
- Volunteers
- 6,908 people
- Sponsor
- Astellas Pharma Europe Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.